HomeQuestion

If approved, do you have any concerns about incorporating gedatolisib into the treatment landscape of HR+/HER2-, PIK3CA wild-type breast cancer (VIKTORIA-1)?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

At what time points during a patient's treatment for metastatic ER+ breast cancer are you checking liquid NGS for endocrine pathway alterations?

In a patient with de novo stage IV breast carcinoma harboring an RB1 Q395* (nonsense) mutation, would treatment with a CDK4/6 inhibitor be appropriate, or should it be avoided due to likely resistance?

How are you approaching endocrine therapy for patients with metastatic HR+/HER2+ breast cancer in light of enhanced HER2 directed treatment with either T-DXd/pertuzumab or HP/tucatinib?

How would you approach treatment selection for an elderly woman with de novo metastatic HER2+ breast cancer with lung and brain mets?

How do you prevent diarrhea in a patient receiving sacituzumab govitecan?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.